A new vaccine to prevent invasive pneumococcal disease and pneumococcal pneumonia in adults has been approved by the US Food and Drug Administration. The injectable drug, Capvaxive (Pneumococcal 21-valent Conjugate Vaccine), protects against 21 serotypes that cause invasive pneumococcal disease in adults, the company said in a news release…
